Back
About the Global Fund
Overview
Impact
Financials
Strategy
Resource MobilizationPeople & Structures
Funding & Implementation
Countries
Regional Applicants
Topics
HIV/AIDS
Tuberculosis
MalariaNews & Stories
Feature Stories
Updates
- Global Health Organizations Commit to New Ways of Working Together for Greater Impact
- WHO and Global Fund Sign Framework Agreement
- Global Fund Partnership Photo Contest: Deadline for Submissions Extended
- Message from the Board Leadership - Governance Review
- Governance Review - Proposed Improvements for the Board and its Committees
- Global Fund Supports Brave Commitments to Ending TB
Documents By Type
Sourcing & Management of Health Products
Information Notice
The Global Fund’s quality assurance information notices provide guidance and advise on how to operationalize in practical terms the consequences of a quality or a safety issue related to a product that has been procured with Global Fund funds. The initial information, stated in the notice, comes from the manufacturer of health products in question and/or is confirmed by stringent regulatory mechanisms.
-
Information Notices
-
Quality Assurance Information Notice 2018-03 (update 1 October 2018): Eligibility Reinstated for Products Manufactured by Diagnostics for the Real World - SAMBA HIV-1 Semi-Q Test for use with SAMBA I Instrument and SAMBA II HIV-1 Semi-Q Test for use with SAMBA II Instrument
download in English -
Quality Assurance Information Notice 2018-04: REMEDICA Rapid Alert Notification CY/I/07/01: Falsified Quinine Sulphate tablets 300 mg
download in English | Français -
Quality Assurance Information Notice 2018-03: Temporary Delisting of Products Manufactured by Diagnostics for the Real World - SAMBA HIV-1 Semi-Q Test for use with SAMBA I Instrument and SAMBA II HIV-1 Semi-Q Test for use with SAMABA II Instrument
download in English -
Quality Assurance Information Notice 2018-02: Dolutegravir (DTG) Use in Women of Childbearing Age – Safety Communication (8 June 2018)
download in English -
Quality Assurance Information Notice 2018-01: Briefing on the Recent Changes to the Global Fund Quality Assurance Policy for Diagnostic Products with Regards to the Procurement and Testing of Malaria Rapid Diagnostic Test (RDTs)
download in English -
Quality Assurance Information Notice 2016-01: All Products Manufactured by Svizera Labs Private Limited, Turbhe, Navi, Mumbai, India - Eligibility Reinstated for Procurement with Global Fund Funds
download in English -
Quality Assurance Information Notice 2017-01: Voluntary Recall Initiated by Lupin for Isoniazid Tablets BP 100mg, Batches No A301856, A302231, A302408
download in English | Español | Français -
Quality Assurance Information Notice 2016-04: Remedica Product: Sulfadoxine / Pyrimethamine, 500/25 mg, Tablets - Eligibility Reinstated for Procurement with Global Fund Funds
download in English -
Quality Assurance Information Notice 2016-03: Hetero Labs Product: Efavirenz, Lamivudine, and Tenofovir, 600/300/300 mg Tablets - No Longer Eligible for Procurement with Global Fund Funds
download in English | Español | Français -
Quality Assurance Information Notice 2016-02: Recommendations Regarding the Procurement and the Distribution of Finished Pharmaceutical Products Using Active Pharmaceutical Ingredients Manufactured at IPCA Ratlam Manufacturing Site
download in English | Español | Français -
Quality Assurance Information Notice 2016-01: Recommendations Following WHO PQP Suspension of all the Prequalified Products Manufactured by Svizera Labs Private Limited
download in English
-
Quality Assurance Information Notice 2018-03 (update 1 October 2018): Eligibility Reinstated for Products Manufactured by Diagnostics for the Real World - SAMBA HIV-1 Semi-Q Test for use with SAMBA I Instrument and SAMBA II HIV-1 Semi-Q Test for use with SAMBA II Instrument
The Global Fund uses cookies for anonymized statistics on website use and content performance. These statistics help us improve and adapt the website for our users.
Please click on "Accept" to agree with the use of these cookies.
To learn more, please read the Privacy Statement.